Benzinga | Oct 27, 2020 09:03AM EDT

Akari Therapeutics To Present Phase II Data From Bullous Pemphigoid Trial At European Academy Of Dermatology And Venereology (EADV) Virtual Congress October 29

* Safety and efficacy data from Phase II clinical trial of nomacopan in adults with mild to moderate BP

* The Phase II data was the basis for the agreement of the FDA and the EMA that Akari may proceed to a Phase III randomised placebo-controlled study using nomacopan for treatment of BP

* Phase III study in both the U.S. and Europe expected to begin in H1 2021

* Nomacopan has been granted orphan drug designation for treatment of BP in the U.S. and Europe

NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces that it will be presenting a poster during the 29th European Academy of Dermatology and Venereology (EADV) Congress being held virtually October 28 -- November 1, 2020. The presentation will be posted onto Akari's website.

The poster presentation will describe the safety and efficacy data from Akari's Phase II clinical trial of nomacopan in adult patients with mild to moderate bullous pemphigoid.

Details of the presentation are as follows:

* Title: A Phase II Clinical Trial of Safety and Efficacy of Nomacopan (rVA576) in Adult Mild-to-moderate Bullous Pemphigoid Patients

* Date/Time: October 29, 2020 at 12:00 CET (7:00 a.m. EDT)

* Location: EADV Virtual Meeting. Registration is required to participate: https://eadvvirtualcongress.org/registration/